Bone Biologics Corp Stock Current Valuation
| BBLGW Stock | USD 20.20 0.00 0.00% |
Valuation analysis of Bone Biologics Corp helps investors to measure Bone Biologics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Bone Biologics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to climb to 0.47 in 2025, whereas Enterprise Value is likely to drop (2 M) in 2025.
Fairly Valued
Today
Please note that Bone Biologics' price fluctuation is relatively risky at this time. Calculation of the real value of Bone Biologics Corp is based on 3 months time horizon. Increasing Bone Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bone stock is determined by what a typical buyer is willing to pay for full or partial control of Bone Biologics Corp. Since Bone Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bone Stock. However, Bone Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.2 | Real 19.39 | Hype 20.2 |
The intrinsic value of Bone Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bone Biologics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bone Biologics Corp helps investors to forecast how Bone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bone Biologics more accurately as focusing exclusively on Bone Biologics' fundamentals will not take into account other important factors: Bone Biologics Corp Company Current Valuation Analysis
Bone Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bone Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Bone Biologics is extremely important. It helps to project a fair market value of Bone Stock properly, considering its historical fundamentals such as Current Valuation. Since Bone Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bone Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bone Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Bone Biologics Corp has a Current Valuation of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Bone Biologics Corp is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about (893,230). Bone Biologics adds roughly 0.0 in current valuation claiming only tiny portion of equities under Health Care industry.Bone Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bone Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bone Biologics' managers, analysts, and investors.Environmental | Governance | Social |
Bone Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.69 | ||||
| Number Of Shares Shorted | 197 | ||||
| EBITDA | (4.22 M) | ||||
| Net Income | (4.11 M) | ||||
| Cash And Equivalents | 4.44 K | ||||
| Total Debt | 377.71 K | ||||
| Book Value Per Share | 1.18 X | ||||
| Cash Flow From Operations | (4.12 M) | ||||
| Earnings Per Share | (0.14) X | ||||
| Beta | 0.93 | ||||
| Total Asset | 3.86 M | ||||
| Retained Earnings | (85.02 M) | ||||
| Working Capital | 3.48 M | ||||
| Net Asset | 3.86 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.